Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2026-02-12 00:00:00 ET · period of report 2026-02-10 · accession 0001104659-26-014546 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-12 | 2026-02-10+ | RYTM | Smith Hunter C | CFO | S - Sale | $100.21 | -7,071 | 123.6K | -5% | -$708.6K |
| DM | 2026-02-12 | 2026-02-11 | RYTM | Smith Hunter C | CFO | A - Grant | $0.00 | +62.5K | 37.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | S | D | 100 | $100.10 | 118,466 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-12 | S | D | 800 | $98.99 | 118,566 | D | — | — | (F9) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.54 to $99.40 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-02-12 | S | D | 400 | $97.67 | 119,366 | D | — | — | (F8) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.18 to $97.85 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-02-12 | S | D | 292 | $96.26 | 119,766 | D | — | — | (F7) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $96.04 to $96.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-02-11 | S | D | 2,266 | $98.37 | 120,558 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.80 to $98.79 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-02-11 | S | D | 100 | $100.85 | 120,058 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.49 to $100.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2026-02-11 | S | D | 400 | $99.44 | 120,158 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.89 to $99.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2026-02-10 | S | D | 700 | $103.68 | 122,924 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.23 to $103.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2026-02-10 | S | D | 100 | $104.76 | 122,824 | D | — | — | |
| 10 | Common | Common Stock | 2026-02-10 | S | D | 1,913 | $102.66 | 123,624 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $$102.09 to $103.02 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 11 | Derivative | Restricted Stock Units | 2026-02-11 | A | A | 25,000 | $0.00 | 25,000 | D | — · — to — | 25,000 Common Stock | (F10) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. (F11) The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. |
| 12 | Derivative | Stock Options (Right to Buy) | 2026-02-11 | A | A | 37,500 | $0.00 | 37,500 | D | $98.47 · — to 2036-02-10 | 37,500 Common Stock | (F12) The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |